More broadly, Matter 1.4 bakes a lot of timing, energy cost, and other automation triggers into the spec, which—again, when ...

Masimo executives are back calling their consumer audio business Sound United, with a senior executive on a conference call ...

Apple and Masimo’s legal battle over the Apple Watch’s Blood Oxygen sensing feature continues this week as both firms meet in ...

Fintel reports that on November 6, 2024, Raymond James upgraded their outlook for Masimo (NasdaqGS:MASI) from Market Perform ...

Approaching One Million Activated TiVo OS Smart TVs; On Track to Achieve Year-End Goal of Two Million Smart TVs Awarded DTS AutoStage Video Win with a ...

Masimo delivered Q3 results that mostly aligned with guidance, yet it faces challenges in its non-healthcare segment.

The consensus rating for Masimo is Buy, based on 2 analyst ratings. With an average one-year price target of $167.5, there's a potential 16.14% upside.

The global non-invasive respiratory monitoring market is poised for substantial growth, projected to increase from an estimated valuation of USD 8.4 Billion in 2023 to USD 15.0 Billion by 2033, at a ...

We recently published a list of 8 Most Promising Medical Stocks According to Hedge Funds. In this article, we are going to ...

The healthcare sector depends on medical technology advancements, particularly devices used in disease prevention, diagnosis, ...

In the latest lawsuit, Apple was awarded $250 in damages – the statutory minimum, which was what the company sought in its ...

A US Court hearing the case of Apple Vs Masimo appear to have given Apple a two finger salute by awarding them US$250, the ...